Home > Haematology > ASH 2020 > Myeloproliferative Neoplasms > Novel, orally available inhibitor of BCL-XL/BCL-2

Novel, orally available inhibitor of BCL-XL/BCL-2

Presented By
Dr Naveen Pemmaraju, MD Anderson Cancer Center, Texas, USA
ASH 2020
Patients being treated with first-line JAK inhibitor monotherapy often relapse [1]. Dr Naveen Pemmaraju (MD Anderson Cancer Center, Texas, USA) presented promising data of an ongoing phase 2 study evaluating navitoclax, a novel, orally available inhibitor of primarily BCL-XL and BCL-2, which are anti-apoptotic members of the BCL-2 family. Myelofibrosis is primarily driven by constitutive activation of the JAK/STAT signalling pathway. This results in increased transcription of growth factors, inflammatory cytokines, and anti-apoptotic proteins such as BCL-XL [2]. Patients with myelofibrosis who have high-molecular-risk mutations, such as those in ASXL1, SRSF2, EZH2, U2AF1, and IDH1/2, at diagnosis will have shorter overall survival (OS) and increased risk of leukaemic transformation [3]. However, there are limited therapeutic options for patients with myelofibrosis who lose response to ruxol...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on